8-K: Perrigo Reports Mixed Q4 and Fiscal Year 2024 Results; Focuses on 'Project Energize' for Future Growth

Perrigo's Q4 results show a slight net sales decline but adjusted EPS growth, while fiscal year results reflect a decrease in net sales offset by adjusted operating income growth driven by 'Project Energize'.

Summary

• Perrigo reported a 1.6% decrease in net sales for Q4 2024, totaling $1.14 billion, but organic growth was 0.7%.
• The decline was attributed to unfavorable impacts from divested businesses, exited product lines, and currency translation.
• Adjusted operating income for Q4 increased by 16.0% to $194 million, driven by benefits from 'Project Energize' and Supply Chain Reinvention programs.
• Adjusted diluted EPS for Q4 was $0.93, an 8.1% increase compared to the prior year.
• For fiscal year 2024, net sales decreased by 6.1% to $4.37 billion, with organic net sales down 4.5%.
• Adjusted operating income for fiscal year 2024 increased by 6.0% to $609 million.
• Adjusted diluted EPS for fiscal year 2024 was $2.57, slightly lower than the $2.58 reported in the prior year.
• The company fully repaid its $400 million 3.9% Senior Notes due December 2024.
• Perrigo's Wisconsin infant formula facility received a 'No Action Indicated' status from the FDA following an inspection.
• Project Energize is expected to deliver annualized pre-tax savings in the range of $140 million to $170 million by 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While net sales declined, the company is showing progress in profitability through cost-saving initiatives like 'Project Energize' and has resolved issues with its infant formula facility. The forward-looking statements are cautiously optimistic.

Positives

• Q4 2024 adjusted EPS increased by 8.1% to $0.93.
• Infant formula net sales grew 17% in Q4 2024 compared to the prior year quarter.
• Adjusted operating margin expanded 260 basis points to 17.0% in Q4 2024.
• Project Energize achieved gross annual savings of approximately $139 million in 2024.
• Perrigo's Wisconsin infant formula facility received a 'No Action Indicated' status from the FDA.
• The company fully repaid its $400 million 3.9% Senior Notes due December 2024.

Negatives

• Net sales decreased by 1.6% in Q4 2024 to $1.14 billion.
• Fiscal year 2024 net sales decreased by 6.1% to $4.37 billion.
• Fiscal year 2024 adjusted diluted EPS was $2.57, slightly lower than the $2.58 reported in the prior year.
• Reported gross margin was 33.9%, a decrease of 300 basis points versus the prior year quarter.
• Adjusted gross margin decreased 260 basis points to 37.2%.

Risks

• The company acknowledges risks related to supply chain impacts, economic conditions, and geopolitical events like the war in Ukraine and conflicts in the Middle East.
• Fluctuations in currency exchange rates and interest rates pose a risk.
• The company faces risks associated with acquisitions, divestitures, and the integration of acquired businesses.
• Adverse results with respect to pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity.

Future Outlook

Management will share the Company's 2025-2027 strategic plan and provide fiscal 2025 guidance at the virtual Investor Day on February 28, 2025.

Management Comments

• President and CEO, Patrick Lockwood-Taylor, stated that Perrigo made substantial progress in rewiring the company through stabilizing CSCA businesses, streamlining operations, and strengthening the company for the long-term.
• Lockwood-Taylor reported that the team achieved full-year adjusted EPS at the midpoint of their guidance range.
• Lockwood-Taylor noted that Perrigo store brand share of infant formula exited 2024 at a high for the year and they remain steadfast in their goal to continue recapturing market share.

Industry Context

Perrigo operates in the consumer self-care products industry, facing competition from other industry participants. The company's performance is influenced by factors such as consumer demand, pricing pressures, and regulatory dynamics, particularly in the infant formula market.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, it mentions that management believes adjusted gross margin and adjusted operating margin are useful for investors to compare and analyze trends in the Company's peer business group and to assist them in comparing the Company's overall performance to that of its competitors.
• Without specific competitor data, it's difficult to assess Perrigo's performance against industry benchmarks.

Stakeholder Impact

• Shareholders: Impacted by the mixed financial results, but may be encouraged by the company's cost-saving initiatives and strategic plans.
• Employees: Affected by restructuring programs like 'Project Energize', which may involve job cuts or changes in roles.
• Customers: May benefit from the company's focus on providing consumer self-care solutions at multiple price points.
• Suppliers: Potentially impacted by the company's supply chain reinvention efforts.
• Creditors: Positively impacted by the company's repayment of its $400 million Senior Notes.

Next Steps

• Management will share the Company's 2025-2027 strategic plan and provide fiscal 2025 guidance at the virtual Investor Day on February 28, 2025.

Key Dates